Tamir Biotechnology

Tamir Biotechnology is a clinical stage anti-viral therapeutics company that engages in discovering and developing new class of prophylactic and therapeutic drugs for the purpose of treating viruses and other pathological conditions.

Tamir Biotechnology's lead asset, ranpirnase, a ribonuclease (RNase), is a member of the superfamily of enzymes that catalyzes the degradation of RNA, and mediate several essential biological activities, including the regulation of cell proliferation, maturation, differentiation, and cell death, and it is therefore, a potential candidate for the development of therapeutics for life-threatening diseases that require anti-proliferative and apoptotic properties.

Orgenesis has acquired Tamir Biotechnology.